《新股消息》樂普生物-B(02157.HK)公開發售超購逾4.6倍及中間價定價 一手中籤率22.3%
腫瘤治療領域的生物製藥企業樂普生物-B(02157.HK)公佈招股結果,每股發售價定爲7.13元,爲招股價範圍(6.87至7.38元)中間價定價。香港公開發售超額認購約4.65倍,每手1,000股計,一手中籤率22.31%,要認購5手即5,000股可穩獲一手。該股將於明日(23日)掛牌。聯席保薦人爲中金及摩根士丹利。
基石投資者維梧資本及King Star合共認購5,464.8萬股公司股份,佔緊隨全球發售完成後已發行股本3.29%。
公司料上市淨集約8.04億元,約68.5%擬用於發展核心產品;約6.3%用於其他主要臨牀階段候選藥物及主要臨牀前候選藥物;約15.8%用於收購有潛力的技術及資產及擴張候選藥物管線;約9.4%用作一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.